Press Releases

Tubulis moves into the Innovation and Startup Center for Biotechnology IZB in Martinsried

MUNICH, GERMANY, July 14, 2022 – It’s time to move for the Tubulis team! We are staying true to our Bavarian roots and are moving into the IZB – Innovation and Startup Center for Biotechnology in Martinsried, south of Munich. We are excited that our team has expanded so quickly that we have outgrown our current offices & lab space and are looking forward to this next chapter for Tubulis GmbH.

Contacts

For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682
Email: tubulis@trophic.eu

Share Article

More Press Releases

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024